- Home
- CLFD vs RGNX Comparison
CLFD vs RGNX Comparison
Compare CLFD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLFD
- RGNX
- Stock Information
- Founded
- CLFD 1979
- RGNX 2008
- Country
- CLFD United States
- RGNX United States
- Employees
- CLFD N/A
- RGNX N/A
- Industry
- CLFD Telecommunications Equipment
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLFD Utilities
- RGNX Health Care
- Exchange
- CLFD Nasdaq
- RGNX Nasdaq
- Market Cap
- CLFD 426.1M
- RGNX 387.0M
- IPO Year
- CLFD N/A
- RGNX 2015
- Fundamental
- Price
- CLFD $37.11
- RGNX $8.85
- Analyst Decision
- CLFD Strong Buy
- RGNX Strong Buy
- Analyst Count
- CLFD 3
- RGNX 8
- Target Price
- CLFD $46.67
- RGNX $31.75
- AVG Volume (30 Days)
- CLFD 185.2K
- RGNX 1.3M
- Earning Date
- CLFD 05-08-2025
- RGNX 05-12-2025
- Dividend Yield
- CLFD N/A
- RGNX N/A
- EPS Growth
- CLFD N/A
- RGNX N/A
- EPS
- CLFD N/A
- RGNX N/A
- Revenue
- CLFD $178,209,000.00
- RGNX $156,718,000.00
- Revenue This Year
- CLFD $10.77
- RGNX $313.52
- Revenue Next Year
- CLFD $14.46
- RGNX N/A
- P/E Ratio
- CLFD N/A
- RGNX N/A
- Revenue Growth
- CLFD N/A
- RGNX 80.70
- 52 Week Low
- CLFD $23.78
- RGNX $5.04
- 52 Week High
- CLFD $44.83
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- CLFD 61.72
- RGNX 51.64
- Support Level
- CLFD $37.49
- RGNX $7.68
- Resistance Level
- CLFD $38.98
- RGNX $9.29
- Average True Range (ATR)
- CLFD 1.52
- RGNX 0.85
- MACD
- CLFD -0.21
- RGNX -0.08
- Stochastic Oscillator
- CLFD 56.54
- RGNX 43.42
About CLFD Clearfield Inc.
Clearfield Inc mainly designs, manufactures, and distributes fiber protection, fiber management and fiber delivery solutions for communications networks. It provides a range of products including copper assemblies, cassettes, box enclosures, fiber connectors, frames, microduct, terminals, vaults, pedestal inserts, FieldSmart, WaveSmart, and CraftSmart. The company has a global presence with the majority of the revenue derived from the United States. The company has two reportable segments namely Clearfield segment and Nestor cables segment. The majority of revenue is derived from Clearfield segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.